Sanofi SA
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
82,878
Stocks News & Analysis
markets
Globalisation declining? Not in investor portfolios
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,847.60 | 205.10 | -2.55% |
| CAC 40 | 7,532.82 | 66.16 | -0.87% |
| DAX 40 | 21,506.28 | 211.11 | -0.97% |
| Dow JONES (US) | 40,545.93 | 1,679.39 | -3.98% |
| FTSE 100 | 8,407.25 | 67.49 | -0.80% |
| HKSE | 22,849.81 | 352.72 | -1.52% |
| NASDAQ | 16,550.61 | 1,050.44 | -5.97% |
| Nikkei 225 | 33,780.58 | 955.35 | -2.75% |
| NZX 50 Index | 12,225.28 | 113.29 | -0.92% |
| S&P 500 | 5,396.52 | 274.45 | -4.84% |
| S&P/ASX 200 | 7,667.80 | 191.90 | -2.44% |
| SSE Composite Index | 3,342.01 | 8.12 | -0.24% |